Furthermore, GLP-1 and FGF21 fusion proteins have been proven to be more potent than a simple mixture of them in activating downstream pathways
W badaniu SELECT (17 604 uczestnikw z chorob sercowo-naczyniow i nadwag/otyoci, bez cukrzycy) semaglutyd 2,4 mg by wizany z 20% redukcj ryzyka powanych zdarze sercowo-naczyniowych (MACE) zgon sercowo-naczyniowy, zawa serca lub udar w porwnaniu z placebo
A Shift Worth Watching Further studies will be needed to establish the long-term safety, durability and optimal use of muscle-preserving therapies in combination with GLP-1 medications, and it is likely to be some years before such combinations, if approved, become part of routine clinical practice in the UK
Hui, H., Farilla, L., Merkel, P